Hematologic Oncology | Specialty

Antibodies From Cured AML Patients Kill Leukemia Cells

June 12th 2016

Patients with acute myeloid leukemia who are cured after allogeneic hematopoietic stem cell transplantation produce antibodies that destroy leukemia cells.

Targeted Therapies Could Revolutionize AML Treatment

June 12th 2016

A host of novel agents that target distinct molecular targets are pushing complete remission rates beyond historical boundaries for patients with acute myeloid leukemia.

Vadastuximab Talirine, HMA Combo Induces Impressive Remissions in AML

June 12th 2016

Frontline treatment with the CD33-directed antibody-drug conjugate vadastuximab talirine plus a hypomethylating agent induced deep and durable remissions for older patients with acute myeloid leukemia.

Stopping TKIs Proven Safe in Chronic Phase CML

June 11th 2016

Tyrosine kinase inhibitors can safely be halted in select patients with chronic phase chronic myeloid leukemia followed a maintained deep molecular remission.

Blinatumomab Nearly Doubles Survival in Acute Lymphoblastic Leukemia

June 11th 2016

The median overall survival with the anti-CD19 immunotherapy blinatumomab was 7.7 months versus 4 months with standard chemotherapy in patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to results from the phase III TOWER study.

Dr. Jae Park on Impact of Disease Burden on CAR T-Cells in Relapsed B-ALL

June 10th 2016

High Response Rates Achieved with Pembrolizumab in Refractory Hodgkin Lymphoma

June 7th 2016

Pembrolizumab (Keytruda) is associated with an exceptional overall response rate in patients with relapsed/refractory Hodgkin lymphoma.

Nivolumab Delivers Durable Responses in Hodgkin Lymphoma

June 6th 2016

Single-agent nivolumab induced responses in 66% of patients with classical Hodgkin lymphoma who had progressed following autologous stem cell transplant and brentuximab vedotin.

Final Phase III Data Uphold CPX-351 Survival Benefit in AML

June 5th 2016

CPX-351 reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary AML.

Dr. Hochhaus on TFS With Nilotinib in Patients With CML

June 4th 2016

Andreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).

New Blockbusters Will Offset Generic Price Erosion in Hematology

May 31st 2016

Hematological practices can expect a slate of new generics to replace long-established brand drugs going off patent, as well as new blockbuster blood therapies that will significantly improve the treatment of some malignancies.

CHMP Backs New Brentuximab Vedotin Indication for Hodgkin Lymphoma

May 28th 2016

The EMA's Committee for Medicinal Products for Human Use has granted a positive opinion to brentuximab vedotin (Adcetris) for use as a consolidation therapy following autologous stem cell transplantation in patients with CD30-positive Hodgkin lymphoma at risk of relapse or progression.

FDA Grants CPX-351 Breakthrough Designation for AML

May 21st 2016

The FDA has granted a breakthrough therapy designation to CPX-351 (Vyxeos) as a treatment for patients with therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

FDA Approves Nivolumab for Hodgkin Lymphoma

May 17th 2016

The FDA approved nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and posttransplantation brentuximab vedotin (Adcetris).

Emerging Approaches in MDS Treatment

May 12th 2016

Rationale for Combination Therapy in MDS

May 12th 2016

Hypomethylating Agents in MDS: Factors to Consider

May 12th 2016

Treatment Goals for Higher Risk MDS

May 12th 2016

Management of Patients with MDS and Cytopenias

May 12th 2016

Options in Low-Risk Myelodysplastic Syndrome

May 12th 2016